免疫療法に敏感な多発転移性鼻がんに対する化学放射線療法戦略:比較症例報告と文献レビュー
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。免疫療法は,転移性鼻がん (NPC) に対して有望である. しかし,結果が異なるため,放射線治療と化学療法のバランスをとって,免疫反応を最適化し,NPC患者の疲労を防ぐ必要があります.
科学分野
- 腫瘍学
- 免疫療法
- 放射線療法
背景
- 鼻がん (NPC) は複雑な悪性腫瘍である.
- 転移したNPCは治療に重大な課題を伴います.
- 免疫療法は 発達したNPCに 新しい治療法を提供しています
研究 の 目的
- 免疫療法で治療された2段階のIVb多発性鼻がん (NPC) の患者で対照的な結果を調べる.
- 併用療法と患者因子の治療反応への影響を分析する.
- 免疫療法で治療されたNPCにおける放射線療法の役割と潜在的な欠点を調査する.
主な方法
- ステージIVbの多発性NPC患者2人のケーススタディ分析
- 免疫療法,化学療法,放射線療法を含む治療法の比較
- 患者のパフォーマンス状態 (ECOG PS) と生存結果の評価
主要な成果
- 症例1: 腫瘍の有意な減少と28ヶ月の生存期間 断続的な免疫療法と化学療法で 患者のパフォーマンスは低下した.
- 症例2: 標準的な化学療法,免疫療法,放射線療法にもかかわらず,迅速な進行と21ヶ月の生存.
- 異なる反応は,治療方法と患者因子の複雑な相互作用を示唆しています.
結論
- 免疫療法と化学療法は,多発性NPCに対する標準的なアプローチです.
- 免疫療法に敏感なNPCにおける放射線療法の役割は,潜在的な免疫細胞損傷のために慎重に検討する必要があります.
- 放射線治療と化学療法のバランスを最適化することは,NPC患者における免疫シネージーの強化と免疫疲労の予防に不可欠です.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...